Summary
Bristol Myers Squibb (BMY) reported its first quarter results for the period ending March 30, 2018, with the filing on April 25, 2018. The company's performance during this quarter provides investors with insights into its ongoing operational efficiency and market positioning. Investors should pay close attention to the company's revenue streams, particularly those driven by key pharmaceutical products, and how the company is managing its expenses and investing in future growth. The report details the company's financial condition and results of operations, as well as its market risk disclosures and controls. This filing is crucial for understanding BMY's financial health, strategic initiatives, and potential risks or opportunities that could impact shareholder value in the near to medium term. Investors are encouraged to review the full MD&A section for a comprehensive understanding of the company's performance drivers and outlook.
Financial Highlights
58 data points| Revenue | $5.19B |
| Cost of Revenue | $1.58B |
| Gross Profit | $3.63B |
| R&D Expenses | $1.25B |
| SG&A Expenses | $980.00M |
| Operating Expenses | $3.41B |
| Interest Expense | $46.00M |
| Net Income | $1.49B |
| EPS (Basic) | $0.91 |
| EPS (Diluted) | $0.91 |
| Shares Outstanding (Basic) | 1.63B |
| Shares Outstanding (Diluted) | 1.64B |
Key Highlights
- 1The filing covers the financial results for the period ending March 30, 2018.
- 2Key financial statements, including Consolidated Statements of Earnings, Balance Sheets, and Cash Flows, are included.
- 3Management's Discussion and Analysis of Financial Condition and Results of Operations provides insights into performance drivers.
- 4Disclosure on Market Risk provides an understanding of potential financial exposures.
- 5Information regarding Legal Proceedings and Risk Factors is presented.
- 6Controls and Procedures are detailed, indicating a focus on internal governance.
- 7Exhibits are provided, which may contain supplementary information relevant to the filing.